Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

62.06 +0.96 (+1.58%)

Streaming Delayed Price Updated: 11:11 AM EST, Feb 27, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,398,547
Open	61.18
Bid (Size)	62.06 (600)
Ask (Size)	62.07 (300)
Prev. Close	61.10
Today's Range	61.18 - 62.13
52wk Range	42.52 - 63.33
Shares Outstanding	2,222,113,553
Dividend Yield	4.06%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

February 26, 2026

From Bristol Myers Squibb

Via Business Wire

Performance

YTD	+16.1%	+16.1%
1 Month	+11.7%	+11.7%
3 Month	+26.1%	+26.1%
6 Month	+32.4%	+32.4%
1 Year	+8.2%	+8.2%

More News

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors ↗

February 18, 2026

Via Chartmill

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

Via FinancialNewsMedia

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

February 23, 2026

Via StockStory

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

Via MarketMinute

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm

February 22, 2026

Via StockStory

Down 25%, Should You Buy the Dip on Bristol Myers Squibb? ↗

February 21, 2026

Via The Motley Fool

2 Incredibly Cheap Dividend Stocks to Buy Now ↗

February 19, 2026

Via The Motley Fool

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Via The Motley Fool

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Via MarketMinute

ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA

February 19, 2026

Via Finterra

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

February 17, 2026

From Bristol Myers Squibb

Via Business Wire

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

Via MarketMinute

The 5 Most Interesting Analyst Questions From Bristol-Myers Squibb’s Q4 Earnings Call

February 12, 2026

Via StockStory

Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss

February 11, 2026

Via Finterra

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Via Finterra

The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff

February 06, 2026

Via MarketMinute

Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model

February 06, 2026

Via Finterra

BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus

February 06, 2026

Via StockStory

Why Bristol Myers Squibb Stock Topped the Market Today ↗

February 05, 2026

Via The Motley Fool

Bristol Myers (BMY) Q4 2025 Earnings Transcript ↗

February 05, 2026

Via The Motley Fool

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?

Yes, Bristol-Myers Squibb is publicly traded.

What exchange does Bristol-Myers Squibb trade on?

Bristol-Myers Squibb trades on the New York Stock Exchange

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange

What is the current price of Bristol-Myers Squibb?

The current price of Bristol-Myers Squibb is 62.06

When was Bristol-Myers Squibb last traded?

The last trade of Bristol-Myers Squibb was at 02/27/26 11:11 AM ET

What is the market capitalization of Bristol-Myers Squibb?

The market capitalization of Bristol-Myers Squibb is 137.92B

How many shares of Bristol-Myers Squibb are outstanding?

Bristol-Myers Squibb has 138B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.